Details for New Drug Application (NDA): 208025
✉ Email this page to a colleague
The generic ingredient in LANSOPRAZOLE is amoxicillin; clarithromycin; lansoprazole. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; lansoprazole profile page.
Summary for 208025
Tradename: | LANSOPRAZOLE |
Applicant: | Dexcel |
Ingredient: | lansoprazole |
Patents: | 2 |
Pharmacology for NDA: 208025
Mechanism of Action | Proton Pump Inhibitors |
Physiological Effect | Inhibition Gastric Acid Secretion |
Medical Subject Heading (MeSH) Categories for 208025
Suppliers and Packaging for NDA: 208025
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LANSOPRAZOLE | lansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208025 | NDA | L. Perrigo Company | 0113-0116 | 0113-0116-55 | 3 CARTON in 1 CARTON (0113-0116-55) / 14 BLISTER PACK in 1 CARTON / 1 TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE in 1 BLISTER PACK |
LANSOPRAZOLE | lansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208025 | NDA | Walgreen Company | 0363-1419 | 0363-1419-55 | 3 CARTON in 1 CARTON (0363-1419-55) / 14 BLISTER PACK in 1 CARTON / 1 TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE in 1 BLISTER PACK |
Profile for product number 001
Active Rx/OTC/Discontinued: | OTC | Dosage: | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | Strength | 15MG | ||||
Approval Date: | Jun 7, 2016 | TE: | RLD: | No | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 21, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 21, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription